

February 9, 2015



Actinium's Chief Medical Officer to Participate in the Next Gen Immunotherapeutics Panel at the 3rd Annual Sachs Cancer Bio Partnering & Investment Forum on February 23rd

Dr. Cicic to Provide Insight Into the Potential Clinical and Therapeutic Benefit of Actimab-A and Iomab-B to Investors and Potential Partners

NEW YORK, NY -- (Marketwired) -- 02/09/15 -- [Actinium Pharmaceuticals, Inc.](http://www.actiniumpharma.com) (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Dr. Dragan Cicic, Chief Medical Officer of Actinium will participate in the Next Gen Immunotherapeutics panel discussion on Monday, February 23, 2015 at 9:45 a.m. as part of the 3rd Annual Sachs Cancer Bio Partnering and Investment Forum in New York, NY.

Dr. Cicic will join leading cancer experts from industry to discuss the increasing role of next generation immunotherapeutics including combination and targeted therapies in Oncology. As part of the panel discussion, Dr. Cicic will provide insight into the potential clinical and therapeutic utility of Actimab-A and Iomab™-B.

Next Gen Immunotherapeutics Panel:

Co-Chaired by

- Mara Goldstein, Managing Director & Senior Biotechnology Analyst, Cantor Fitzgerald
- Raffaele Baffa, Senior Director, Translational and Experimental Medicine, Sanofi Aventis SA

Panelists:

- Doug Plessinger, VP, Clinical and Medical Affairs, Argos Therapeutics, Inc.
- Dragan Cicic, CMO, Actinium Pharmaceuticals, Inc.
- Gil Beyen, Chairman and CEO, Erytech Pharma
- Greg Naeve, Head of Strategic Research Partnerships, Oncology, Pfizer
- Marc Mansour, CEO, Immunovaccine Technologies
- Paul Higham, Managing Director, immatics biotechnologies GmbH
- Robert Petit, CSO, Advaxis Inc.

[The 3rd Annual Sachs Cancer Bio Partnering & Investment Forum](#) is designed to bring

together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding/investment. Sachs forums are recognized as the leading international stage for those interested in investing in the biotech and life science industry and are highly transactional. They draw together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharmas.

Members of the investment community who are interested in meeting with management should contact Evan Smith, CFA of Actinium Pharmaceuticals at (646) 840-5442 or esmith@actiniumpharma.com.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical lomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of lomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:

Actinium Pharmaceuticals, Inc.
Evan Smith, CFA
VP Investor Relations and Finance
(646) 840-5442
esmith@actiniumpharma.com

Source: Actinium Pharmaceuticals